Zacks Research Raises Earnings Estimates for DENTSPLY SIRONA

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Zacks Research lifted their Q3 2026 earnings per share estimates for DENTSPLY SIRONA in a report released on Tuesday, May 26th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $0.37 per share for the quarter, up from their previous estimate of $0.36. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.42 per share.

Several other analysts have also recently commented on the company. Mizuho dropped their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Citigroup started coverage on DENTSPLY SIRONA in a research report on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. UBS Group dropped their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Finally, Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $13.82.

DENTSPLY SIRONA Stock Up 0.1%

Shares of XRAY opened at $10.00 on Thursday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA has a one year low of $9.40 and a one year high of $17.09. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -3.17, a PEG ratio of 1.19 and a beta of 0.93. The stock has a 50 day moving average price of $11.33 and a 200 day moving average price of $11.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million for the quarter, compared to analysts’ expectations of $841.80 million. During the same quarter in the previous year, the firm posted $0.43 earnings per share. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director James D. Forbes bought 5,000 shares of the company’s stock in a transaction on Monday, March 9th. The stock was bought at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gregory T. Lucier bought 15,000 shares of the company’s stock in a transaction on Monday, March 9th. The stock was bought at an average price of $12.45 per share, with a total value of $186,750.00. Following the completion of the acquisition, the director owned 65,000 shares in the company, valued at $809,250. This represents a 30.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 70,000 shares of company stock valued at $956,437. 0.50% of the stock is owned by company insiders.

Institutional Trading of DENTSPLY SIRONA

Several large investors have recently added to or reduced their stakes in the stock. Southpoint Capital Advisors LP acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at $116,000,000. AQR Capital Management LLC lifted its stake in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Armistice Capital LLC lifted its stake in shares of DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock valued at $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock valued at $58,480,000 after purchasing an additional 4,003,606 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: DENTSPLY SIRONA announced it is expanding its U.S. distribution network through a broader partnership with Nashville Dental, Inc., which should improve access to its digital dentistry solutions in key regional markets and may help sales momentum. Article Title
• Neutral Sentiment: The company presented at the Stifel Jaws & Paws Conference 2026, which can keep investors focused on management’s strategic outlook, but the transcript itself does not indicate a major new catalyst. Article Title
• Negative Sentiment: Zacks Research cut earnings estimates across several future periods, including FY2026, FY2027, and FY2028, while keeping a Hold rating. Lower profit expectations can weigh on the shares because they suggest slower earnings growth than previously expected.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.